Indoco Remedies Croissance future

Future contrôle des critères 4/6

Indoco Remedies devrait augmenter ses bénéfices et son chiffre d'affaires de 72.2% et de 11.7% par an respectivement. Le BPA devrait croître de de 70.7% par an. Le rendement des capitaux propres devrait être 12.1% dans 3 ans.

Informations clés

72.2%

Taux de croissance des bénéfices

70.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	17.9%
Taux de croissance des recettes	11.7%
Rendement futur des capitaux propres	12.1%
Couverture par les analystes	Low
Dernière mise à jour	26 Oct 2024

Mises à jour récentes de la croissance future

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Recent updates

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

May 24

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Jan 26

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Jan 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Sep 16

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

May 21

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Aug 31

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Jul 04

Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price

Mar 09

What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?

Feb 22

Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?

Feb 07

Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 17

Is Indoco Remedies (NSE:INDOCO) A Risky Investment?

Dec 27

Calculating The Intrinsic Value Of Indoco Remedies Limited (NSE:INDOCO)

Dec 06

What Type Of Shareholders Own The Most Number of Indoco Remedies Limited (NSE:INDOCO) Shares?

Nov 14

Prévisions de croissance des bénéfices et des revenus

NSEI:INDOCO - Estimations futures des analystes et données financières antérieures (INR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2027	23,285	1,799	1,379	2,654	3
3/31/2026	20,523	1,239	470	2,102	5
3/31/2025	17,509	247	-796	2,212	4
9/30/2024	17,732	321	-3,076	2,220	N/A
6/30/2024	18,223	767	N/A	N/A	N/A
3/31/2024	18,173	985	-2,706	1,567	N/A
12/31/2023	17,958	1,016	N/A	N/A	N/A
9/30/2023	17,356	1,134	-911	1,442	N/A
6/30/2023	16,869	1,281	N/A	N/A	N/A
3/31/2023	16,686	1,423	-284	1,788	N/A
12/31/2022	16,496	1,569	N/A	N/A	N/A
9/30/2022	16,084	1,617	85	1,703	N/A
6/30/2022	15,622	1,537	N/A	N/A	N/A
3/31/2022	15,408	1,548	485	1,738	N/A
12/31/2021	14,368	1,393	N/A	N/A	N/A
9/30/2021	14,110	1,317	257	1,391	N/A
6/30/2021	13,524	1,157	N/A	N/A	N/A
3/31/2021	12,415	930	54	822	N/A
12/31/2020	12,084	734	N/A	N/A	N/A
9/30/2020	11,654	571	387	931	N/A
6/30/2020	11,298	393	N/A	N/A	N/A
3/31/2020	11,066	241	644	1,228	N/A
12/31/2019	10,909	302	N/A	N/A	N/A
9/30/2019	10,640	264	N/A	N/A	N/A
6/30/2019	10,071	111	N/A	N/A	N/A
3/31/2019	9,684	-29	352	1,321	N/A
3/31/2018	10,424	412	N/A	1,227	N/A
3/31/2017	10,968	771	N/A	886	N/A
3/31/2016	10,081	819	N/A	1,122	N/A
3/31/2015	8,570	828	N/A	1,090	N/A
3/31/2014	7,336	580	N/A	988	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de INDOCO ( 72.2% par an) est supérieure au taux d'épargne ( 6.7% ).

Bénéfices vs marché: Les bénéfices de INDOCO ( 72.2% par an) devraient croître plus rapidement que le marché Indian ( 17.9% par an).

Croissance élevée des bénéfices: Les bénéfices de INDOCO devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de INDOCO ( 11.7% par an) devrait croître plus rapidement que le marché Indian ( 10.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de INDOCO ( 11.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de INDOCO devrait être faible dans 3 ans ( 12.1 %).

Indoco Remedies Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 27%

Recent updates

MD & Executive Director recently bought ₹4.6m worth of stock

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)

Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Dividend of ₹1.50 announced

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation

Consensus EPS estimates fall by 20%

First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024)

Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Now 21% overvalued

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

Consensus EPS estimates fall by 16%

Full year 2024 earnings: EPS misses analyst expectations

Now 24% overvalued

Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Consensus EPS estimates fall by 27%

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Consensus EPS estimates fall by 13%

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 11%

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Indoco Remedies Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings released: EPS ₹4.52 (vs ₹2.78 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

First quarter 2022 earnings released: EPS ₹4.30 (vs ₹1.85 in 1Q 2021)